These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Successful treatment of concurrent chemoradiotherapy for stage I nasal NK/T cell lymphoma: a report of two cases.
    Author: Niibe Y, Hayakawa K, Kitano M, Ishiyama H, Nakayama M, Yao K, Okamoto M.
    Journal: Anticancer Res; 2005; 25(6C):4403-6. PubMed ID: 16334116.
    Abstract:
    Nasal natural killer/T cell (NK/T cell) lymphoma is a rare subtype of lymphomas, being a subtype of non-Hodgkin's lymphoma with a much worse prognosis than other subtypes. One reason for this worse prognosis is that nasal NK/T cell lymphoma is resistant to standard sequential chemoradiotherapy. Thus, we adopted concurrent chemoradiotherapy using a CHOP-like regimen for treating stage I nasal NK/T cell lymphoma. Case 1 was treated with concurrent chemoradiotherapy using 41-Gy irradiation with 12 cycles of the CHOP-like regimen (THP-CVP). Case 2 was treated with concurrent chemoradiotherapy using 50-Gy irradiation with 10 cycles of THP-CVP. In both Case I and Case 2, the tumors disappeared after chemoradiotherapy. The Case 1 patient is still alive with 45 months free of relapse. The Case 2 patient is also still alive with 39 months free of relapse. These results suggest that concurrent chemoradiotherapy using a CHOP-like regimen for stage I nasal NK/T cell lymphoma provided sufficient dose intensity and may be a useful treatment option.
    [Abstract] [Full Text] [Related] [New Search]